A New Targeted Option for Metastatic Pancreatic Cancer, Explained

For decades, RAS mutations, which drive the vast majority of pancreatic cancers, were considered “undruggable.” That changed on August 26, 2026, with the U.S. Food and Drug Administration (FDA) approval of daraxonrasib (Rasonque), the first RAS-targeted therapy approved for metastatic pancreatic adenocarcinoma. Meredith Pelster, M.D., M.S.C.I., associate director of gastrointestinal cancer research and chair of the Gastrointestinal Cancer Research Executive Committee at Sarah Cannon Research Institute, explains how this approval reshapes the conversation she’s able to have with newly diagnosed patients, moving beyond chemotherapy alone to a plan with a genuine next step.

Pelster walks through what the trial data actually mean for patients’ day-to-day lives, not just survival statistics, but tangible improvements in symptoms, energy and quality time with loved ones. She also shares what she observed in patients treated through the drug’s Expanded Access Program before formal approval, and what she wants every pancreatic cancer patient and their family to know about molecular testing, clinical trials and where treatment is headed next.

For a patient newly diagnosed with metastatic pancreatic cancer today, what does this approval change about the conversation you’re able to have with them?

Meredith Pelster, M.D., M.S.C.I.: It changes the shape of the conversation. For a long time, when I sat down with a patient with metastatic pancreatic cancer, I was talking almost entirely about chemotherapy and about managing expectations. Now I can also talk about a targeted option. Daraxonrasib (Rasonque) was approved on August 26, 2026, for adults with metastatic pancreatic adenocarcinoma who have had at least one prior systemic therapy, or who aren’t candidates for multidrug chemotherapy — and it’s the first RAS-targeted therapy approved in this disease.

Practically, that means two things. First, molecular testing matters, and I bring it up at the first visit rather than later. RAS mutations drive the large majority of pancreatic cancers, and knowing a patient’s tumor profile now genuinely changes what I can offer. Second, I can lay out a plan that has a next step in it. Being able to say “here is what we do first, and here is what we do after that” is a very different conversation than the one I was having before this approval.

Nearly doubling survival time is a striking result. In practical terms, what might that mean for a patient’s day-to-day life, their symptoms, their ability to spend time with family, beyond just the number itself?

MP: In the RASolute 302 trial, median overall survival was 13.2 months with daraxonrasib versus 6.7 months with standard chemotherapy. But the numbers I find just as meaningful are the ones underneath it: The cancer was held in check longer (median progression-free survival of 7.2 months versus 3.6) and tumors shrank in about 30% of patients versus 11% with chemotherapy.

That’s what translates into daily life. Time when the disease isn’t growing is usually time when a patient feels more like themselves. Tumor shrinkage can mean less pain, better appetite, more weight held on, less of the fatigue that comes with progressing disease. And this is a once-daily pill taken at home rather than infusion days at a cancer center, which gives people back hours and, honestly, gives back a sense of normal life. That’s the difference between months spent recovering from treatment and months spent at a grandchild’s graduation, on a trip that mattered, or simply at their own kitchen table.

I’m careful not to oversell it. This is not a cure, and it isn’t side-effect-free. Rash and other skin effects, mouth sores and diarrhea are common and need active management, and there are less common but serious risks like lung inflammation that we watch closely. But quality of that additional time is a real part of what we’re seeing, not just quantity.

Some patients were able to access daraxonrasib before formal approval through the Expanded Access Program. What did you see in those patients’ experiences that gives you a sense of what this treatment is really like to go through?

MP: My experience with patients treated on the EAP mirrors the data from the RASolute 302 trial. Most patients experience rash; however, only a minority experience rash or any other side effect, such as mouth sores or nail changes, that require a dose hold or dose reduction. Overall, even patients with significant rash tell me that taking this drug is preferable to chemotherapy.

What I can say generally is that the toxicities are different from chemotherapy toxicities, not simply fewer. They’re largely skin, mouth and GI, they tend to show up early, and they are very manageable when the team is proactive about them. Patients do best when they know what to look for from day one and call us early rather than waiting.

Patients with pancreatic cancer often face limited options and a lot of uncertainty. What would you want someone facing that diagnosis right now to know about where treatment stands and where it’s headed?

MP: I’d want them to know three things.

First, this is not the same disease landscape it was five years ago. RAS was called “undruggable” for four decades. It isn’t anymore. That change happened within many of my patients’ own treatment journeys.

Second, ask for molecular testing of your tumor, early. It is the single most useful thing a patient or family member can advocate for, because it determines what the cancer’s driver mutation is and what targeted options are available. Even though daraxonrasib is approved for all patients regardless of molecular testing, I still want to know the mutation profile. If there is not a RAS mutation, there is likely another, rare driver such as NRG-1 fusion. Or there may be other alterations, such as MTAP loss, that can be targeted in a clinical trial.

Third, ask about clinical trials at every decision point, not just at the end. Daraxonrasib exists today because patients enrolled in trials when it was still an unproven idea, and the next several options are moving through trials right now.

As research continues into using daraxonrasib earlier in treatment or in different disease settings, what does that mean for hope, both for patients today and for those who may be diagnosed in the future?

MP: The current approval is for patients who’ve already had one line of therapy. The obvious question, and the one being studied now, is what happens when you use a drug like this earlier, when patients are stronger, tumors are less resistant and the disease has had less time to adapt. I am particularly eager to see if using targeted therapy in patients whose disease has not metastasized could allow more patients to undergo curative intent surgery. Studies are also looking at combinations and at other RAS-driven cancers, since RAS mutations aren’t unique to pancreatic cancer.

For a patient diagnosed today, the practical hope is that they may have more than one option in sequence. For someone diagnosed a few years from now, I think there’s a real chance the standard first conversation looks quite different from the one I have today.